Boehringer Ingelheim and Eli Lilly presented full results from the landmark EMPEROR-Preserved Phase III trial, demonstrating that empagliflozin showed a 21 percent relative risk reduction for…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.